Mission Pharmacal hitches onto TriLogic's delivery tech

TriLogic Pharma has found a new partner for its drug-delivery technology. Mission Pharmacal plans to use TriLogic's delivery tech to develop women's healthcare products, under a deal that gives San Antonio-based Mission a license to the platform for its programs. Financial details of the agreement were not disclosed.

Montgomery, AL-based TriLogic says that drug-delivery platform, TRI-726, can release many active ingredients over a matter of hours or days, using a liquid-to-gel formulation and materials that can be safely absorbed in the body. The company markets animal health products such as anti-bacterial toothpaste and surgical gels used in orthopedic procedures on animals, according to the firm's website.

"Mission Pharmacal's growth over the last 60 years has been the result of good relationships with other innovative pharmaceutical companies. We look forward to working with TriLogic and its new technology," Terry Herring, president of Mission Pharmacal's commercial operations, said in statement.

- here's the release
- see the San Antonio Business Journal's piece

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.